1,972 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Ausbil Investment Management Ltd

Ausbil Investment Management Ltd purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,972 shares of the company's stock, valued at approximately $601,000.

Several other institutional investors and hedge funds have also bought and sold shares of MEDP. SBI Securities Co. Ltd. purchased a new position in shares of Medpace during the fourth quarter worth $31,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the period. Assetmark Inc. boosted its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the last quarter. Finally, Colonial Trust Co SC boosted its stake in shares of Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after buying an additional 105 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent research reports. Mizuho lowered their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Truist Financial cut their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. Robert W. Baird decreased their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Finally, Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Trading Up 2.2%

MEDP stock opened at $309.36 on Monday. The business's fifty day moving average price is $299.87 and its 200 day moving average price is $321.16. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The company has a market capitalization of $8.89 billion, a PE ratio of 23.62, a P/E/G ratio of 5.58 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same quarter in the prior year, the company earned $3.20 earnings per share. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.30% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.